Stocks · News reference
This is an initial public offering of shares of common stock of Latigo Biotherapeutics, Inc. We are offering 16,000,000 shares of our common stock to be sold in this offering.Prior to this offering, there has been no
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company reported $0.00 in
Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.